FDA Approval Sought for New Generic Version of Advair Diskus

FDA Approval Sought for New Generic Version of Advair Diskus

291413

FDA Approval Sought for New Generic Version of Advair Diskus

Lannett is seeking the approval of a generic form of Advair Diskus (fluticasone-salmeterol powder) in the U.S. Such an approval would be expected to provide a less-expensive alternative to the inhalation treatment that generated about $3 billion in total U.S. sales for the 12 months ending in February 2021, according to Lannett.  Originally developed by GlaxoSmithKline (GSK), Advair Diskus is approved as a maintenance therapy to ease breathing difficulties in patients with chronic obstructive pulmonary disease…

You must be logged in to read/download the full post.